Fig 1: Immunocytochemical staining of vCor.4UTM cells (red: alpha-actinin)
Ventricular hypertrophy is indicative of a number of cardiovascular diseases, the most common disease type in developed countries. Ventricular cardiomyocytes exhibit electrophysiological and contracting properties distinct from those of atrial cardiomyocytes. Axiogenesis has developed human induced pluripotent stem (iPS) cell-derived primary-like ventricular cardiomyocytes, named vCor.4UTM cells, for research and drug development purposes.
vCor.4UTM ventricular cardiomyocytes hold antibiotic resistance under a ventricular cardiomyocyte - specific promoter, and can be selected to yield a 100% pure cell culture of cardiac cells without fibroblasts. vCor.4UTM human iPS cell-derived ventricular cardiomyocytes comprise approximately 90% ventricular and 10% atrial and pacemaker phenotype. Acting together, vCor.4UTM iPSC – derived ventricular cardiomyocytes replicate an in vivo cellular environment, including ventricular-like action potentials, pharmacology and morphology.
Advantages of vCor.4UTM human iPSC – derived cardiomyocytes:
- Primary-like ventricular cardiomyocytes of human origin
- Ready-to-use (just thaw and plate)
- Suitable for co-culture and organotypic 3D culture assays with FibroCor.4U cells
vCor.4UTM cardiomyocytes are delivered pre-matured for short pre-culture times, and have been validated in the following applications:
- Manual patch clamp
- Impedance measurements
- Cell contraction force (in 2D co-culture with FibroCor.4UTM cells)
Fig. 2: Application of E-4031 (Manual patch clamp: Current clamp recording)